```html

Zafirlukast Side Effects – A Comprehensive Medical Guide

Overview

Zafirlukast (brand name Accolate) is a leukotriene receptor antagonist (LTRA) used primarily for the chronic management of asthma and for the relief of allergic rhinitis. It works by blocking leukotrienes – inflammatory chemicals released in the lungs and nasal passages that cause airway narrowing, mucus production, and swelling.

While the medication is generally well‑tolerated, it can cause a range of side effects, from mild gastrointestinal upset to rare but serious reactions such as liver injury or neuropsychiatric events. Understanding these potential adverse effects helps patients and clinicians monitor therapy safely.

• Who may be affected: Adults and children ≥5 years old who are prescribed zafirlukast for asthma or allergic rhinitis. Children under five are not approved for this drug.
• Prevalence: In clinical trials, approximately 10–20 % of patients reported at least one adverse event, most of which were mild. Serious adverse events occurred in <1 % of users.<sup>[1] Mayo Clinic</sup>
• Regulatory status: Approved by the U.S. FDA in 1996; still listed on the WHO Essential Medicines List for asthma.

Symptoms

Side effects can be grouped by the body system they affect. Not every patient will experience all of these, and many resolve after a short period.

Common (≥5 % of users)

• Headache – dull or throbbing pain, often mild.
• Nausea or vomiting – usually occurs within the first few days of therapy.
• Diarrhea – watery stools, sometimes accompanied by abdominal cramping.
• Upper‑respiratory symptoms – sore throat, hoarseness, or a dry cough.
• Rash or mild skin itching – often maculopapular, may improve with antihistamines.

Uncommon (1–5 % of users)

• Dyspepsia (indigestion) – burning sensation in the upper abdomen.
• Joint or muscle pain – may mimic arthralgia.
• Fever – low‑grade, transient.
• Elevated liver enzymes – detected on routine labs, usually reversible.

Rare (<1 % of users) but important to recognize

• Hepatotoxicity – jaundice, dark urine, right‑upper‑quadrant pain, markedly elevated ALT/AST.
• Neuropsychiatric effects – agitation, anxiety, depression, suicidal thoughts, or vivid dreams.
• Hypersensitivity reactions – angio‑edema, urticaria, bronchospasm, or anaphylaxis.
• Churg‑Strauss syndrome (eosinophilic granulomatosis with polyangiitis) – rare vasculitic disease presenting with fevers, skin lesions, peripheral neuropathy, and pulmonary infiltrates.

Causes and Risk Factors

Zafirlukast itself does not “cause” disease; rather, side effects arise from how the drug interacts with the body’s metabolism and immune system.

Mechanistic causes

• Leukotriene pathway blockade – while beneficial for asthma, it may alter normal immune surveillance, leading to rash or, rarely, hypersensitivity.
• Hepatic metabolism – zafirlukast is metabolized by CYP3A4 and CYP2C9. Accumulation in patients with liver impairment can precipitate hepatotoxicity.
• Blood‑brain barrier penetration – small amounts cross into the CNS, which may explain neuropsychiatric symptoms in susceptible individuals.

Risk factors for specific side effects

• Liver disease or alcohol use – ↑ risk of elevated transaminases or fulminant hepatitis.
• Concomitant CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) – increase drug levels.
• History of psychiatric illness – higher likelihood of mood changes.
• Prior drug allergy or eosinophilic disorders – predispose to hypersensitivity or Churg‑Strauss.
• Older age (>65) – reduced hepatic clearance, more comorbidities.

Diagnosis

Because most side effects are identified by symptoms, a systematic approach helps differentiate a medication reaction from disease progression.

Clinical Evaluation

1. History – review timing of symptom onset relative to first dose, dose changes, and other new medications.
2. Physical examination – look for rash, jaundice, abdominal tenderness, or neuropsychiatric signs.

Laboratory Tests

• Liver function panel (ALT, AST, ALP, bilirubin) – baseline before starting therapy; repeat if symptoms arise.
• Complete blood count (CBC) with differential – eosinophilia may hint at hypersensitivity or Churg‑Strauss.
• Renal function (BUN, creatinine) – not directly affected but useful for overall assessment.

Special Tests (if indicated)

• Ultrasound or CT of the abdomen – if liver injury is suspected.
• Psychiatric screening tools (PHQ‑9, GAD‑7) – when mood changes occur.
• Allergy testing – skin prick or serum IgE if an allergic reaction is unclear.

Treatment Options

Management depends on the severity of the side effect.

General measures

• Continue monitoring – many mild symptoms improve without stopping the drug.
• Symptomatic relief – antacids for dyspepsia, antihistamines for rash, anti‑emetics for nausea.

When to discontinue zafirlukast

• Signs of serious liver injury (ALT/AST >3× upper limit of normal with symptoms).
• Severe or progressive rash, angio‑edema, or anaphylaxis.
• New or worsening psychiatric symptoms, especially suicidal ideation.
• Confirmed diagnosis of Churg‑Strauss syndrome.

Alternative or adjunct medications

• Other LTRAs – montelukast (Singulair) is often better tolerated, though cross‑reactivity can occur.
• Inhaled corticosteroids (ICS) – first‑line for persistent asthma; may reduce need for LTRAs.
• Long‑acting β2‑agonists (LABA) – for patients needing additional bronchodilation.
• Biologic agents (e.g., omalizumab, mepolizumab) – for severe asthma unresponsive to standard therapy.

Management of specific adverse events

• Hepatotoxicity – stop zafirlukast, monitor liver enzymes weekly until normalization, consider hepatology referral.
• Neuropsychiatric symptoms – discontinue drug, arrange prompt mental‑health evaluation, consider alternative asthma controller.
• Hypersensitivity – immediate discontinuation, antihistamines, and—if anaphylaxis—epinephrine administration per emergency protocols.

Living with Zafirlukast Side Effects

Even mild side effects can impact daily life. Below are practical tips to minimize discomfort while staying on therapy when appropriate.

• Take with food – reduces nausea and abdominal upset.
• Stay hydrated – helps prevent constipation and supports liver function.
• Maintain a medication diary – record dose timing, symptoms, and any triggers.
• Use over‑the‑counter (OTC) remedies cautiously – discuss with your clinician before adding antacids, antihistamines, or pain relievers.
• Schedule regular lab checks – at least every 3–6 months for liver enzymes if you have risk factors.
• Mindful of mental health – talk openly with family or a counselor if you notice mood swings; early detection is key.
• Allergy alert – carry a card or smartphone note describing your medication and known reactions.

Prevention

While not all adverse effects are preventable, risk can be substantially lowered.

Before starting therapy

• Obtain baseline liver function tests.
• Review medication list for CYP3A4 or CYP2C9 inhibitors.
• Screen for psychiatric history.

During treatment

• Adhere to the prescribed dose – do not double up if a dose is missed; take the next dose at the usual time.
• Avoid excessive alcohol intake (≥2 drinks/day) which stresses the liver.
• Report any new rash, jaundice, or mood changes promptly.
• Use sun protection – some skin reactions may be photosensitive.

Complications

If side effects are ignored or not managed appropriately, several complications can arise.

• Progressive liver injury – may lead to acute liver failure requiring transplantation.
• Severe hypersensitivity – airway swelling can cause respiratory arrest.
• Psychiatric crisis – untreated depression or suicidal ideation can result in self‑harm.
• Exacerbation of asthma – abrupt discontinuation without an alternative controller may trigger attacks.
• Churg‑Strauss syndrome – a life‑threatening vasculitis that can affect the heart, kidneys, and nervous system.

When to Seek Emergency Care

---

Sources: [1] Mayo Clinic. “Zafirlukast (Oral Route) Proper Use.” Updated 2023.
[2] CDC. “Asthma – Managing Medications.” 2022.
[3] National Institute of Allergy and Infectious Diseases (NIAID). “Leukotriene Modifiers.” 2021.
[4] WHO Model List of Essential Medicines, 22nd edition, 2023.
[5] Cleveland Clinic. “Drug‑Induced Liver Injury.” 2022.

```